Unique ID issued by UMIN | UMIN000044937 |
---|---|
Receipt number | R000051328 |
Scientific Title | The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer |
Date of disclosure of the study information | 2021/07/21 |
Last modified on | 2022/12/28 12:38:08 |
The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer
The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer
The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer
The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer
Japan |
Lung cancer
Pneumology |
Malignancy
NO
To clarify the clinical effect of immune checkpoint inhibitors combined with anti-angiogenic agents
Others
To evaluate the differences in effectiveness depending on the timing and order of administration of concomitant drugs
The primary endopoint are overall survival, progression-free survival,and overall response rate.
Others,meta-analysis etc
Not applicable |
Not applicable |
Male and Female
NSCLC patients who received immune checkpoint inhibitors and anti-angiogenic agents combination therapy or either monotherapy
Patients without data about survival or tumor response
2000
1st name | Kinnosuke |
Middle name | |
Last name | Matsumoto |
Osaka University Graduate School of Medicine
Department of Pulmonology
565-0871
Yamadaoka, Suita
+810668793831
m.kinnosuke@gmail.com
1st name | Kinnosuke |
Middle name | |
Last name | Matsumoto |
Osaka University Graduate School of Medicine
Department of Pulmonology
565-0871
Yamadaoka, Suita
+810668793831
m.kinnosuke@gmail.com
Osaka University
None
Other
None
None
None
None
NO
2021 | Year | 07 | Month | 21 | Day |
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=268286
Published
https://www.sciencedirect.com/science/article/abs/pii/S0169500221006012
2414
ICI and AA therapy had significantly higher ORR than either monotherapy. PFS and OS were favorable benefits in ICI and AA therapy; however, significant heterogeneity was identified in these analyses. According to the administration timing and sequence, ICI immediately after AA showed no PFS and OS benefits compared to ICI monotherapy, whereas favorable PFS and OS were demonstrated when AA was concomitantly administered with ICI or when AA was administered immediately after ICI.
2022 | Year | 12 | Month | 28 | Day |
The inclusion criteria were as follows: (I) observational studies or randomized controlled trials involving NSCLC patients who received both ICI and AA concomitantly or sequentially with or without cytotoxic chemotherapies (e.g. atezolizumab + bevacizumab + carboplatin + paclitaxel, bevacizumab + cisplatin + pemtrexed to nivolumab, pembrolizumab to ramucirumab + docetaxel); (II) comparative studies of concomitant or sequential ICI and AA therapy versus either monotherapy (Fig. 1); (III) studies with data on response rate or survival data or both; and (IV) articles written in English. We excluded reviews, case reports, animal studies, or duplicate publications.
The study protocol was registered in the International Prospective Register of Systematic Reviews CRD 42021268286. Our systematic review and meta-analysis followed PRISMA guidelines. Some databases, including PubMed-MEDLINE, Embase-Scopus, and Web of Science were searched for eligible studies published before August 23, 2021.
Not evaluated.
The primary endpoint was the efficacy of ICI and AA therapy compared to ICI or AA monotherapy, including the odds ratio (OR) for ORR and the HR for PFS and OS.
Completed
2021 | Year | 07 | Month | 21 | Day |
2021 | Year | 07 | Month | 21 | Day |
2021 | Year | 07 | Month | 22 | Day |
2021 | Year | 07 | Month | 28 | Day |
2021 | Year | 08 | Month | 20 | Day |
Study Search
Studies will be systematically searched through PubMed-MEDLINE and EMBASE-Scopus, as of July 21, 2021.
The search strategy will be as follows:
# non-small cell lung cancer
AND
# immune checkpoint inhibitor
AND
# anti-angiogenic agents
should be included.
Data synthesis
From the data obtained, the efficacy of immune checkpoint inhibitors and anti-angiogenic agents will be compared to the monotherapy.
Statistical significance will be judged by P < 0.05.
2021 | Year | 07 | Month | 21 | Day |
2022 | Year | 12 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051328